Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs XOMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 9–1 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: VNDA 1 – 4 XOMA (1 Tie) Matrix Metrics: VNDA 1 – 9 XOMA

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin).

  • Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. VNDA 49.0/100 HOLD) and 0.68β · 37% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs XOMA
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06

6-Pillar Scorecard Institutional Category Breakdown (VNDA 1 – 4 XOMA)

Columns: Metric · VNDA · XOMA
1. Valuation Multiples XOMA
Forward P/E 103.1x 21.5x
Trailing P/E 103.1x 28.2x
PEG Ratio 2.23x N/M
EV / Revenue 0.9x 16.1x
2. Growth & Scale VNDA
Revenue Growth (YoY) +24.1% -22.6%
Earnings Growth (YoY) -95.9% +207.9%
TTM Revenue (USD) $229M $49M
Market Cap $238.9M $781.8M
3. Profitability & Quality XOMA
Gross Margin 93.6% 99.0%
Operating Margin -77.6% -3.9%
Net Profit Margin -119.9% 69.6%
Return on Equity (ROE) -82.5% 34.2%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) -$150M $8.3M EBITDA
Cash Flow Margin -65.4% 17.1% EBITDA Mgn
Net Cash / Leverage $40M Net Cash $7.79 Book/Sh · 34.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XOMA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 163.3% (75th %ile) 101.5% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (1) vs XOMA (9)
Institutional Metric VNDA XOMA Criterion Row Edge
Market Capitalization
Scale
$238.9M $781.8M Larger Scale XOMA
Trailing P/E Ratio
Valuation
103.1x 28.2x Lower Multiple XOMA
Forward P/E Ratio
Valuation
103.1x 21.5x Lower Multiple XOMA
Revenue Growth (YoY)
Growth
+24.1% -22.6% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% -3.9% Higher Margin XOMA
Net Profit Margin
Profitability
-119.9% 69.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
-82.5% 34.2% Higher ROE XOMA
52-Week Range Position
Momentum
4% ($4–$10) 78% ($22–$45) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 0.68β · 37% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$229M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 99.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) $8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VNDA +3.31 pp
VNDA: -0.5% · XOMA: -3.81%
3M Horizon XOMA +26.24 pp
VNDA: -16.9% · XOMA: +9.34%
6M Horizon XOMA +52.52 pp
VNDA: -18.26% · XOMA: +34.26%
1Y Horizon VNDA +13.65 pp
VNDA: +38.25% · XOMA: +24.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VNDA vs XOMA. Trailing 12-month operating profitability (VNDA -77.6% vs XOMA -3.9%) and valuation multiples (VNDA 103.1x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

VNDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$229M
Gross Margin93.6%
Op. Margin-77.6%
ROE / Fwd P/E-82.5% · 103.1x
XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs XOMA Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. VNDA 49.0/100 HOLD) and 0.68β · 37% Vol risk profile, whereas VNDA leads top-line expansion (+24.1% YoY revenue growth, 2.23x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, VNDA generates $229M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.

XOMA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus XOMA (34.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.